Hepatic fibrosis is the result of an excessive wound-healing response subsequent to chronic liver injury. A feature of liver fibrogenesis is the secretion and deposition of extracellular matrix proteins by activated hepatic stellate cells (HSCs). Here we report that upregulation of EphB2 is a prominent feature of two mouse models of hepatic fibrosis and also observed in humans with liver cirrhosis. EphB2 is upregulated and activated in mouse HSCs following chronic carbon tetrachloride (CCl 4 ) exposure. Moreover, we show that EphB2 deficiency attenuates liver fibrosis and inflammation and this is correlated with an overall reduction in pro-fibrotic markers, inflammatory chemokines and cytokines. In an in vitro system of HSCs activation we observed an impaired proliferation and sub-optimal differentiation into fibrogenic myofibroblasts of HSCs isolated from EphB2−/− mice compared to HSCs isolated from wild type mice. This supports the hypothesis that EphB2 promotes liver fibrosis partly via activation of HSCs. Cellular apoptosis which is generally observed during the regression of liver fibrogenesis was increased in liver specimens of CCl 4 -treated EphB2−/− mice compared to littermate controls. This data is suggestive of an active repair/regeneration system in the absence of EphB2. Altogether, our data validate this novel pro-fibrotic function of EphB2 receptor tyrosine kinase.
. To date, a smattering of studies have highlighted key functional properties of the Eph/Ephrin molecules that are also relevant to liver fibrosis 1 . Interaction between EphB4 and Ephrin B2 has been found to modify recruitment of liver sinusoidal endothelial cells and VEGF production, both critical events that are required for the development of hepatic fibrosis 16 . Ephrin-B2 ligand has also been shown to influence the formation and function of hepatic vascular structure by modulating Platelet derived growth factor receptor-β (PDGFR-β) signaling 17 . EphB2 is the most upregulated of the EphB/EphrinB molecules in hepatocellular carcinoma, the end-stage of liver fibrosis/cirrhosis 18 possibly linking upregulation of EphB2 with disease progression. EphB2 is an axon guidance cue that was originally identified as a critical mediator of axonogenesis during the early stage of the CNS development 19, 20 ; emphasizing the link between developmentally regulated pathways and fibrogenesis 1 . Indeed, EphB2 has also been found to be upregulated in fibroproliferative membrane in ocular diseases 21 , psoriatic epidermis 22 , skin wounding 23 , idiopathic pulmonary fibrosis 24 and in fibrotic scar following CNS injury 25 . We previously showed that EphB2 receptor was upregulated in the livers of mice with malaria-causing Plasmodium infection and was implicated in mouse malaria-associated hepatic fibrosis 26 . However, it remains to be determined whether EphB2 could also be involved in non-pathogen driven liver inflammation and fibrosis.
In this report, we provide substantial evidence linking upregulation of EphB2 with liver fibrogenesis in non-pathogen driven mouse models of hepatic fibrosis. We demonstrate that EphB2 is critical for the optimal trans-differentiation of quiescent HSCs into fibrogenic myofibroblasts and accordingly EphB2 deficiency attenuates hepatic fibrosis in mice. Collectively our data confirm the pro-fibrogenic function of EphB2 receptor that could be potentially targeted for anti-fibrotic therapies.
Results
EphB2 is upregulated in the liver after fibrotic injury. Previously, we reported that EphB2 is upregulated in fibrotic livers of mice infected with blood stage Plasmodium parasites 26 . To ascertain whether this observation is also relevant during liver fibrosis in non-infectious settings in mice, we determined the mRNA expression profile of EphB receptors and Ephrin-B ligands in two mouse models of hepatic fibrosis: chronic administration of the hepatotoxic chemical carbon tetrachloride (CCl 4 ) and the MDR2-null mice fed a normal rodent laboratory diet to induce biliary fibrosis 27 . Using real-time quantitative PCR (RT-qPCR), we found that the mRNA levels of Eph-B2, B3, B4 and B6, but not EphB1 receptors were upregulated in liver tissues of CCl 4 -treated mice compared to oil-treated controls mice (Fig. 1a) . EphB2 was transcriptionally the most upregulated of the EphB receptors (EphB2~30-fold compared to EphB3~8-fold, EphB4~4-fold and EphB6~10-fold) (Fig. 1a) . RNA transcripts of Ephrin-B ligands were also elevated in the livers of CCl 4 -treated mice relative to oil-treated controls mice (EphrinB1~17-fold, EphrinB2~15-fold and EphrinB3~10-fold) (Fig. 1a) . Immunofluorescence staining of liver sections confirmed an increase in EphB2 protein in CCl 4 -treated mice compared to oil-treated control mice and the specificity of EphB2 antibody used was further validated by an absence of staining in liver sections of EphB2−/− mice (Fig. 1b) .
To ascertain whether EphB2 upregulation could also be observed during acute CCl 4 -mediated liver injury, we screened for EphB2 mRNA levels after administration of one, three and six doses of CCl 4 . Our data show that EphB2 mRNA levels increase specifically after repetitive administration of at least 6 doses of CCl 4 ( Supplementary  Fig. S1A ). The latter findings clearly indicate that EphB2 transcripts upregulation is mainly observed during chronic CCl 4 intoxication and this is mirrored by transcription of fibrogenic markers collagen type 1-α-1 chain (COL1α1) and α-smooth muscle actin (αSMA), ( Supplementary Fig. S1B,C) .
In the MDR2-null mouse model of biliary fibrosis, we also found that the mRNA levels of Eph-B1, B2, B3 and B6, but not EphB4 receptors were upregulated in the livers of MDR2-null mice at week 25 compared to control mice (Fig. 1c) . Interestingly, EphB2 mRNA transcripts were again prominent (EphB2~13-fold compared to EphB1~4-fold, EphB3~5-fold and EphB6~6-fold) (Fig. 1c ) and this was replicated by an immunofluorescence analysis depicting an upregulation of EphB2 protein level in liver sections of MDR2-null mice compared to control mice (Fig. 1d) . However, transcripts for Ephrin-B ligands were marginally upregulated in MDR2-null mice; ≤2-fold for each gene (Fig. 1c) .
Having established that EphB2 is the most highly upregulated of the EphB receptors in both the CCl 4 and MDR2-null mouse models of hepatic fibrosis, we next determined the human relevance of our findings by screening for EphB2 expression in human biopsies specimen of cirrhotic livers. In most cases EphB2 proteins were elevated in liver cirrhosis but virtually undetected in normal liver ( Supplementary Fig. S2 ). Altogether, this data demonstrates that upregulation of EphB2 is a feature of mouse and human liver fibrosis.
EphB2 is expressed and activated on HSCs in fibrotic liver. To determine which cell type within the liver contributes to the observed increase in EphB2 during liver fibrosis we carried out cell fractionation on livers from CCl 4 -treated and oil-treated mice. We determined mRNA levels of EphB2 and Ephrin-B ligands in each cell type isolated (liver sinusoidal endothelial cells (LSEC), hepatocytes (HEP), HSCs and macrophages). No major change in EphB2 mRNA levels was observed in LSEC or HEP during CCl 4 -induced liver fibrosis (Fig. 2a) . However, relative to livers from oil-treated control mice, EphB2 mRNA was upregulated in HSCs ~7-fold and CD11b macrophages ~2 fold isolated from CCl 4 -treated mice. Interestingly, whilst EphrinB3 mRNA was upregulated in both HSCs and CD11b+ macrophages from CCl 4 -treated mice relative to oil treated control mice (~6 fold in both cell types), expression of EphrinB1 and EphrinB2 mRNA followed the same trend as EphB2 with respect to being highly upregulated in HSCs (~10-fold for both genes) compared to CD11b+ macrophages (Fig. 2a) EphB2 and Ephrin-B ligands in CCl 4 -induced liver fibrosis. Confirmation of the EphB2 transcriptome profiles was provided by immunofluorescence analysis of liver sections from oil and CCl 4 -treated mice stained with EphB2 and αSMA antibodies. Most of EphB2 staining co-localized with α-SMA (Fig. 2b) suggesting that activated HSCs do upregulate EphB2 during liver fibrogenesis in this model. This finding is significant because HSCs are the main cellular source of collagen in CCl 4 -induced hepatic fibrogenesis 4, 28, 29 .
To determine whether EphB2/Ephrin-B system is activated during liver fibrogenesis, we stained liver sections from CCl 4 -treated mice with an antibody that detect phosphorylated EphB1/EphB2 as a read-out for activated EphB2. These sections were co-stained with platelet derived growth factor receptor-β (PDGFRβ), another fibrogenic marker of activated HSCs 30 .
We noted an increase in phospho-EphB1/EphB2 that strongly co-localized with PDGFRβ expression in CCl 4 -treated mice (Fig. 2c) . This data suggest that EphB2 receptor signaling (forward signaling) is induced on activated HSCs in the fibrotic liver microenvironment.
Expression of EphB2 on HSCs is associated with the differentiation of quiescent HSCs into fibrogenic myofibroblasts in vitro. It is well established that when cultured into plastic dishes, quiescent HSCs transdifferentiate into fibrogenic myofibroblasts as evidenced by their change in morphology and increased expression of fibrogenic molecules including COL1α1 and α-SMA 31, 32 . We next investigated the possibility of a temporal correlation between expression of EphB2 and one of its ligands Ephrin-B1 with differentiation of HSCs in vitro. We noted a gradual increase in EphB2 and αSMA mRNA and protein levels in HSCs after three and six days in culture (Fig. 3a,b) . Interestingly, Ephrin-B1 and COL1α1 mRNA were also elevated in these same culture-activated HSCs. This data shows that expression level of EphB2 is correlated with the differentiation of quiescent HSCs into fibrogenic myofibroblasts in vitro.
EphB2 deficiency attenuates CCl 4 -induced hepatic fibrosis in mice. To determine whether EphB2 expression is required for the development of liver fibrosis, we made use of EphB2-deficient 19 and littermate control mice that were chronically treated with CCl 4 twice a week for 6 weeks. Compared to similarly treated wild type littermate controls, CCl 4 -treated EphB2−/− mice had reduced liver fibrosis (Fig. 4) . Sirius red and Masson-trichrome staining of liver sections demonstrated a reduction of collagen deposition (P < 0.05) in the livers of CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate controls (Fig. 4a,b,d ). This observation was further supported by hydroxyproline quantitation of collagen which was reduced in CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate controls (Fig. 4c) . We also observed a drastic reduction in mononuclear cells infiltrating in the liver of CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate controls ( Supplementary Fig. S3 ).
Alpha-smooth muscle actin (α-SMA) has been suggested to be a potential marker of liver activated HSCs since its expression increases dramatically during differentiation of quiescent HSCs into myofibroblasts. Following α-SMA immunofluorescence staining of liver sections, we noted a significant reduction (P < 0.05) of α-SMA expression in the livers of CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate controls (Fig. 4e,f) . This observation was further supported by transcriptional analyses showing a significant reduction (P < 0.05) of the mRNA levels of αSMA as well as some major pro-fibrotic markers genes namely COL1α1, PDGFRβ and tissue inhibitor of metalloproteinase (TIMP1) in the livers of CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate controls (Fig. 4g) . Collectively, this data demonstrates involvement of EphB2 receptor in the pathological mechanism of hepatic fibrosis in this model.
EphB2 is required for a robust hepatic inflammatory response during liver injury. Fibrosis
is usually accompanied by the release of pro-fibrotic and inflammatory cytokines/chemokines in the affected organs, with transforming growth factor-β1 (TGF-β1) being a principal mediator of fibrogenesis 33 . Given that CCl 4 -treated EphB2−/− mice developed less fibrosis compared to CCl 4 -treated littermates, we hypothesized that this observation may be related to a defective inflammatory response in the liver following injury. We noted that TGF-β1 mRNA was downregulated in the livers of CCl 4 -treated EphB2−/− mice ( Fig. 5a ) and this was correlated by a decrease in peripheral total TGF-β1 in the plasma (Fig. 5b) .
TGF-β1 binds to type I and type II TGFβR serine/threonine kinases on the surface of HSCs which then triggers the phosphorylation of SMAD2 and SMAD3 in the cytoplasm that will then form a complex with SMAD4. This SMAD complex translocate in the nucleus and recognizes SMAD-binding elements on the genome; regulating expression of pro-fibrotic genes 33 . Given that transcription of TGF-β1 was reduced in the livers of CCl (Fig. 5c ). This data is consistent with the reduction of liver fibrosis we observed in EphB2−/− mice following chronic CCl 4 liver injury. Next, we determined whether the reduction of liver fibrosis in CCl 4 -treated EphB2−/− mice was also associated with a decrease in pro-inflammatory cytokines and chemokines. RNA transcripts for tumor necrosis factor-α (TNF-α), interleukin(IL)-1β and IL-6 genes were all significantly downregulated in the livers of CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated littermate control animals ( Fig. 5d ) and this was mirrored by a significant reduction in the plasma level of total IL-1β and IL-6 (Fig. 5e) . The levels of T-box 21 and GATA-3 mRNA, representative of Th1 and Th2 transcriptions factors respectively, were also significantly decreased in fibrotic livers of EphB2−/− mice compared to intact littermate controls (Fig. 5f ). Thus, it is possible that EphB2 might be playing a role in the maintenance of both Th1-related inflammation and Th2-related fibrogenesis.
Several chemokine/chemokine receptor pathways have been linked to the pathogenesis of liver fibrosis by promoting the recruitment of monocytes/macrophages to the site of liver injury. Consistent with our data showing that EphB2 deficiency impacts the recruitment of immune cells to the site of liver injury ( Supplementary Fig. S3 ), transcripts for the chemokine receptors (CCR1, CCR2 and CCR5) and chemokine ligands (CCL2, CXCL2 and CXCL10) were all downregulated in the livers of CCL 4 -treated EphB2−/− mice compared to CCl 4 -treated littermates (Fig. 5g) . Thus, EphB2 might be required for the substantial hepatic inflammatory response that accompanies fibrosis.
Analysis of liver enzyme damage indicated a trend toward a reduction of plasma ALT in CCl 4 -treated EphB2−/− mice compared to CCl 4 -treated EphB2+/+ mice although this trend did not reach statistical significance (Fig. 5h ).
EphB2 deficiency mitigates in vitro differentiation of HSCs into myofibroblasts. Having shown
that EphB2 expression is elevated on HSCs during liver fibrosis and that it is required for TGF-β1 signaling and CCl 4 -induced hepatic fibrosis in mice, we next hypothesized that EphB2 deficiency could dampen the differentiation of HSCs into fibrogenic myofibroblasts. To test this hypothesis, we isolated HSCs from EphB2+/+ and EphB2−/− and allowed them to differentiate into myofibroblasts in vitro. After six days of culture, we noted a sub-optimal differentiation of quiescent HSCs into myofibroblasts from EphB2−/− mice compared to HSCs isolated from littermate controls. Immunofluorescence staining of day 6 culture-activated HSCs with anti-α-SMA antibody demonstrated that EphB2−/− HSCs have less stress fibers and also incorporated less α-SMA protein into stress fibers compared to EphB2+/+ HSCs (Fig. 6a) . Immunoblotting of day 6 culture-activated HSCs with anti-α-SMA antibody further supported a defective activation of HSCs isolated from EphB2−/− mice compared to HSCs isolated from EphB2+/+ mice (Fig. 6b) . In addition, we noted a reduction in mRNA levels of α-SMA, COL1-α1 and PDGFR-β in EphB2−/− culture-activated HSCs compared to HSCs isolated from littermate controls (Fig. 6c) . Altogether, our data imply that culture-activated HSCs poorly transdifferentiate into fibrogenic myofibroblasts in the absence of EphB2.
To ascertain whether this sub-optimal activation of EphB2−/− myofibroblasts could be due to their susceptibility to apoptosis in vitro we used a TUNEL assay. We observed an increased in apoptosis in day 6 culture-activated HSCs isolated from EphB2−/− mice compared to HSCs isolated from EphB2+/+ mice (Fig. 6d,e) . We also noted that proliferation of fibrogenic myofibroblasts, as assessed by BrdU incorporation, was indeed attenuated in the absence of EphB2 (Fig. 6f) . Taken together our data suggest that in the absence of EphB2, culture-activated HSCs are more prone to apoptosis and have a defective proliferation rate in vitro.
Elevated apoptosis in the liver of EphB2−/− mice following CCl 4 injury. To counteract fibrosis-inducing insults in the liver, apoptosis is a key mechanism to thwart fibrogenesis. Since CCl 4 -treated EphB2−/− mice have reduced fibrosis relative to wild type littermate control animals, we hypothesized that this could be the result of an increased in apoptosis of fibrogenic cells in the liver. TUNEL staining of liver sections of CCl 4 -treated EphB2−/− mice displayed a significant elevation in apoptosis compared to CCl 4 -treated littermate controls (Fig. 7a,b) supporting a role for EphB2 in suppressing apoptosis and repair mechanisms upon chronic liver injury. This may explain the limited fibrosis that occurs in EphB2−/− mice upon CCl 4 -induced chronic liver injury.
Discussion
Fibrosis is a complex pathology affecting various organs including the liver, lung, heart, kidney, bone, skin, eye and even the central nervous system (CNS) 34 . In the present study, we have shown that EphB2 is potentially a critical regulator of liver inflammation and fibrogenesis. In human, EphB2 was initially found to be highly upregulated in hepatocellular carcinoma, the end-stage of liver fibrosis/cirrhosis 18 . Our current work in mouse models of hepatic fibrosis have identified EphB2 mRNA transcripts as the most upregulated of the five EphB receptors in fibrotic livers of CCl 4 and MDR2-null mice. This appears to be a general trend in mice as transcription of EphB2 was also elevated in STAM ™ mice, a newly developed animal model of non-alcoholic steatohepatitis (NASH) compared to control animals (data not shown). Furthermore, our human biopsy data showing that EphB2 expression is upregulated in liver cirrhosis ( Supplementary Fig. S2 ) indicates that these observations have relevance to human liver fibrosis. All this evidence, coupled to our previous work showing increase EphB2 expression in the liver of malaria-infected mice 26 , collectively suggest that EphB2 upregulation is likely a basic response to chronic liver injury-inducing fibrosis, regardless of the initiating agent. As such, understanding the mechanisms by which EphB2 promote fibrosis would potentially enable development of novel EphB2-based anti-fibrotic therapy. Hepatic fibrosis is the result of a chronic inflammatory process affecting various liver cell subtypes 6 . The inflammatory insult generates a microenvironment that promotes the synthesis and deposition of extracellular matrix (ECM) proteins by activated HSCs, the primary source of ECM proteins in the liver. It is also well documented that in order to efficiently produce ECM, quiescent HSCs must undergo a transformation into fibrogenic myofibroblasts 34 . Eph/Ephrin signaling is known to regulate cell proliferation, migration and tissue remodelling 35 which are core events occurring during the reprogramming of HSCs into fibrogenic myofibroblasts both in vitro and in vivo 4 . Our data support a role specifically for EphB2 in these processes. Although EphB2-deficient mice appear "normal", and are fertile, they do have an inherent defect especially in establishing a precise organization of tissues during the development of embryonic organs 19, 36 . Furthermore, an improper migration or seeding of immune cells within lymphoid organs like the thymus has been observed in these mice 37 . Interestingly, developmental pathways (like the Eph/Ephrin family) involved in tissue patterning during embryogenesis appear to be modulated in organs fibrosis 24 . Consequently, we were able to show that the developmental guidance cue EphB2 is actively signaling in the fibrotic liver. Furthermore we have shown that modulation of EphB2 expression predominantly occurs in HSCs (Fig. 2) and transdifferentiation of quiescent HSCs into fibrogenic myofibroblasts requires EphB2 (Fig. 6) . It is likely that EphB2 expression in other cells within the liver microenvironment like immune cells (macrophages etc), LSECs and HEPs also regulate hepatic fibrogenesis. Future studies will tackle this point by targeted-deletion of EphB2 in various liver cell type during fibrogenesis.
Reprogramming of HSCs requires TGF-β1 signaling. EphB2 has previously been identified as a new target for TGF-β signaling, influencing migration and invasion of breast cancer cells 38 and in a separate study the positioning of proliferating cells within the colonic crypts of intestine partly depends on EphB2/SMAD3 signaling 39 .
Here we show that in the absence of EphB2 hepatic TGF-β1 mRNA and plasma levels were downregulated in EphB2−/− mice following CCl 4 exposure when compared to intact littermate control mice (Fig. 5) . Consistent with these observations we also noted a reduction in phosphorylated SMAD2/SMAD3 signaling molecules downstream TGFβRI/II activation pathway in the livers of EphB2−/− mice following CCl 4 exposure. Thus, it is plausible that EphB2 promotes the differentiation of HSCs into fibrogenic myofibroblasts by modifying TGB-β1 production and/or signaling.
Other than links to TGF-β1 signaling relatively little is known about the molecular mechanisms or machinery used by EphB2 to facilitate the formation of myofibroblasts from HSCs precursors. However it is tempting to speculate that the cytoplasmic domain of EphB2 containing a tyrosine kinase domain and a PDZ-binding motif can serve as docking site for mechanosensitive factors such as Yes-associated protein 1 (YAP1) and the transcriptional coactivator with PDZ-binding motif (TAZ) which are core mediators of myofibroblasts activation during fibrogenesis 40, 41 . Indeed the same intracellular domain of EphB2 closely interacts with myosin1b, a motor protein implicated in the redistribution of myosin II in actomyosin fibers that facilitate changes in cell morphology, a biological process observed during myofibroblasts biogenesis 42 .
Since liver inflammation and fibrosis are interconnected 6 , the reduction in the degree of fibrosis in EphB2-deficient animals chronically exposed to CCl 4 led us to question whether these mice also have a defective inflammatory response, in addition to the reduction in TGF-β1. Indeed we noticed that EphB2-deficient mice have a drastic reduction of proinflammatory cytokines and chemokines responsible for the maintenance of a profibrotic state in injured liver 43, 44 . Our data corroborate recent findings linking EphB2 activation with the regulation of TNFα/NF-κB axis in hepatocytes 26 as well as in CNS diseases 45 and this strengthens the possible crosstalk between both the EphB2/NF-κB (pro-inflammatory state) and EphB2/TGF-β (pro-fibrotic state) signaling axes. Further research is needed to understand how activation of the EphB2/EphrinB signaling modulate both the NF-κB and TGF-β signaling pathways. EphB2 receptor could potentially be targeted to induce regression of liver fibrosis, a process that is characterized by the reduction in the number of activated HSCs/myofibroblasts due to a combination of cellular senescence as well as apoptosis in HSCs 46 . Indeed, we noted a consistent reduction of HSCs expressing α-SMA and PDGFR-β (Figs 4e and 5c) as well as a drastic increase in apoptosis in EphB2-deficient CCl 4 -exposed mice compared to littermate controls (Fig. 7) . This data supports a role for EphB2 deficiency in limiting fibrosis and potentially promoting repair of liver tissue in the face of chronic fibrotic injury.
In summary, this study highlights EphB2 as a key fibrogenic molecule involved in the development and progression of hepatic fibrosis. Pending further validation with specific pharmacological inhibitor, EphB2 could potentially be a novel therapeutic target for the treatment of liver fibrosis/cirrhosis.
Methods
Mice. Female MDR2-null (abcb4−/−) 27 , FVB control and C57BL/6 wild type (WT) mice aged 6-8 weeks were bred in-house or purchased from The Jackson laboratory (Bar Harbor, ME, USA). Female EphB2−/− mice 19 on a C57BL/6 background were re-derived (a kind gift from Dr. Jonathan Gibbins, University of Reading, UK) and bred in-house under a heterozygous breeding system. Mice were given water and food (LabDiet, MO, USA: chow 5001) ad libitum and housed under standard conditions. All experiments were approved and carried out according to protocols approved by the Institutional Animal Care and Use Committee of the University of Utah and Emory University following the National Institute of Health guidelines for the care and use of laboratory animals.
CCl 4 model of hepatic fibrosis. Mice aged 6-8 weeks were injected intraperitoneally with 2 µl/g of CCl 4 (Sigma) (adjusted to 10% concentration in olive oil) or olive oil twice a week for 6 weeks. Mice were sacrificed by CO 2 inhalation 72 hours after the last dose of CCl 4 and the livers removed and processed for further analysis. For an acute CCl 4 -mediated liver injury, mice were administered one dose (24-hour), three doses (three times a week) and six doses (three times a week for two weeks) of 10% CCl 4 or vehicle (oil) and sacrificed by CO 2 inhalation 24 h later.
MDR2-null model of biliary fibrosis.
The MDR2-null model of biliary fibrosis has been described elsewhere 27 . Briefly, MDR2−/− mice and controls on FVB background were fed a normal rodent laboratory diet for 25 weeks until which they were sacrificed and the livers excised and processed for further analysis.
Hepatic stellate cell isolation. Livers from individual mice were sequentially perfused through the inferior vena cava with Krebs-Ringer bicarbonate buffer followed by 0.3% pronase (Roche) and 0.3 mg/ml type IV collagenase (Sigma). Then excised, minced with scissors and further digested with 0.1 mg/ml collagenase/dispase (Roche) supplemented with 0.008% deoxyribonuclease I (Roche). The cells suspensions were shaken (250 rpm) at 37 °C for 20 min and filtered through a 70 µm sterile cell strainer. To remove hepatocytes, the cells suspensions were centrifuged at 90 g for 5 min, and the supernatant collected. The latter was further centrifuged at 400 g for 10 min at 4 °C to collect the nonparenchymal fraction. Collected cells were resuspended in 5 ml 17% OptiPrep ™ gradient density (Sigma) and 5 ml of 11.5% OptiPrep ™ was gently added followed by 2 ml of Gey's balanced salt solution GBSS (Sigma). The cell suspension was centrifuged at 1400 g for 20 min at 4 °C and the cells layered between the 11.5% OptiPrep ™ and GBSS representing HSCs were carefully aspirated, resuspended in completed medium (DMEM supplemented with 5mM L-Glutamine, 20 mM HEPES, 1 nM sodium pyruvate, 1× β-mercaptoethanol, 1× penicillin/streptomycin and 20% FCS). The cells were centrifuged at 400 g for 10 min, counted and plated on either a 96-well, 24-well plate (Nunc) or 8-well chamber slides for microscopy. These primary HSCs were cultured for at least 6 days at 37 °C in a CO 2 incubator to progressively differentiate into myofibroblasts.
Isolation of other nonparenchymal cell fraction. This was partly achieved following the procedure outline above for isolation of HSCs and completed as described elsewhere 28 . Briefly after the livers were perfused and the hepatocytes isolated as described above, the nonparenchymal cells fraction (consisting of HSCs, portal fibroblasts, macrophages, bone marrow cells, endothelial cells, etc) was recovered. HSCs were isolated as described above. Macrophages and endothelial cells were isolated by gradient centrifugation in 15% Nycodenz followed by magnetic sorting with anti-CD11b and anti-CD31 antibodies conjugated beads (Miltenyi Biotec).
RNA extraction and cDNA synthesis. Cells or tissues were homogenized in RNA Stat60 ® and total RNA extracted using standard phenol-chloroform protocols followed by DNase treatment of the extracted RNA using RNA-II purification kit (Nachery-Nagel). A total of 100 ng of RNA per sample was converted into cDNA using Superscript II (Life Technologies) at 42 °C for 50 min, 70 °C 15 min, in the presence of 5 uM oligo (dT) [16] [17] [18] Quantitative PCR. Real-time qPCR reactions were performed using Quantitect SYBR Green PCR reagent (Qiagen). PCR amplification was performed with 5 µl cDNA sample (diluted 1:10), 2 µM of each primer, 7 µl of QPCR SYBR green mix and plates run using Applied BioSystems FAST 7000 Sequence detection system (ABI Prism FAST 7000). Primer sequences are shown in Supporting Table S1 . Transcripts were normalized to two different housekeeping genes (Ubiquitin and β-actin) and mRNA expression levels calculated using the 2 −ΔΔCt method.
Immunohistochemistry and immunofluorescence. Paraffin-embedded sections were processed for immunohistochemistry following standard protocols 30 . Five micron (5 µm) sections were stained with Hematoxylin and Eosin, picrosirius red, and Masson-trichrome (Sigma) to assess collagen deposition. Quantification of collagen from picrosirius red stained sections was achieved as previously described 26 . For immunofluorescence staining, liver tissues were fixed with 4% paraformaldehyde overnight at 4 °C, immersed in graded sucrose solutions, embedded in OCT (Tissue Tek) and stored at −80 °C until sectioned using a Cryostat (10 µm). HSCs cultured on chamber glass slides were also fixed with 4% paraformaldehyde for 30 min. After blocking, cells and frozen liver sections were incubated overnight at 4 °C with the following primary antibodies: Human/mouse EphB2 clone AF467 (1:50; R&D Systems), phospho-EphB1/EphB2 Y594 ab61791 (1:200; Abcam), phospho-SMAD2/SMAD3 D27F4 (1:100; Cell signaling); α-SMA clone 1A4 (1:100, Sigma), CD140b (PDGFR-β) APB5 (1:50, eBioscience). Cells or liver sections were then stain with NorthernLights 493 ® or NorthernLights 577 ® conjugated secondary antibodies for one hour (1:500 R&D Systems). The nuclei were counterstained with mounting medium containing DAPI (VectorShield). Images were captured using a Carl Zeiss confocal microscope. Digital morphometric measurement of α-SMA were performed using Image J software. Ten random fields from each section were analyzed.
Staining of human biopsy specimen. Paraffin-embedded human hepatic tissues arrays (LV805a) from normal and patients with hepatic cirrhosis were purchased from US Biomax Inc. These slides were stained for human/mouse EphB2 and α-SMA as described above.
Hydroxyproline assay. Liver tissues were homogenized and baked overnight at 105 °C in 12 N HCl.
Hydroxyproline content was determined using a kit following the manufacturer's instructions (BioVision).
Plasma cytokines analysis.
Cytokines analysis from plasma samples were performed using Singleplex Luminex ® kit for each analyte tested according to the manufacturer's instructions (Invitrogen, ThermoFisher Scientific).
Liver damage enzyme detection. Plasma samples from oil and CCl 4 -treated mice were processed in a single batch for determination of serum alanine aminotransferase (ALT) level using a DC Element chemistry analyser (HESKA).
Western blot. Liver tissues and cells lysates were prepared with RIPA buffer containing 1× EDTA/ proteinase-phosphatase inhibitor cocktail (Pierce). The lysate supernatant was stored at −80 °C until used for immunoblotting. Protein extracts were separated by SDS-PAGE electrophoresis and blotted onto nitrocellulose membrane. Blots were incubated overnight with the following primary detection antibodies: anti-α-SMA EPR5368, (1:2000, Abcam); anti-GAPDH GA1R and anti-β-actin (1:10000 ThermoFisher Scientific). The blots were then incubated with IRDye ® IgG secondary antibody conjugates (Li-Cor) and then revealed using an Odyssey ® gel documentation system following the manufacturer's instruction (Li-Cor).
Apoptosis assay. Apoptosis was evaluated in culture-activated HSCs and in frozen liver sections of mice chronically exposed to CCl 4 using the In Situ Cell Death Detection Kit (Roche) following the manufacturer's instruction. Images were captured using a confocal microscope and data analysed with ImageJ software.
Cell proliferation assay. To assess HSCs proliferation, the BrdU assay was performed using the BrdU Cell Proliferation ELISA Kit (Abcam). A total of 1 × 10 4 purified HSCs from EphB2−/− and WT littermates were plated in each well of a 96 well plate and culture for 6 days, with BrdU incorporated for the final 18 h of culture. The assay was performed following the manufacturer's protocol.
Statistical analysis.
Statistical analyses were performed with the GraphPad Prism software 5.0 (Graph Pad software, USA) using the non-parametric Mann Whitney-U test. Values of p < 0.05 were considered statistically significant.
